IL6 and metabolic dysfunction-associated steatohepatitis: discovered that targeting YTHDF1 with siRNA enhances anti‐tumour immunity in NASH–HCC by inhibiting the EZH2‐IL6 pathway, augmenting the efficacy of anti‐PD1 therapy.